FREE COURSE AVAILABLE IN ENGLISH, SPANISH, FRENCH, AND ITALIAN

In recent years, the treatment of multiple myeloma (MM) has advanced with the inclusion of immunomodulatory agents, monoclonal antibodies, and proteasome inhibitors. However, MM patients often develop resistance, leading to relapsed/refractory multiple myeloma (RRMM). Thus, there is a critical need for therapies with new mechanisms of action to treat RRMM patients and manage the disease long-term. In this context, B-cell maturation antigen (BCMA)-directed therapies have emerged as a promising option.

This UEMS-accredited course provides an overview of BCMA-directed therapies for RRMM, covering their efficacy, mechanisms of action, safety, and biomarkers for selection. The course also explores treatment sequencing strategies and practical clinical cases.

Course Highlights:
➡️ Modalities of BCMA-directed therapies: ADCs, CAR T, TCEs
➡️ Biomarkers for treatment selection
➡️ Treatment sequencing and practical clinical cases

Enroll now to enhance your knowledge in managing RRMM and optimize patient outcomes 👉 [ Ссылка ]

This activity is supported by an Independent Medical Education grant from Pfizer.

___________
Multiple myeloma, RRMM, BCMA-directed therapies, B-cell maturation antigen, multiple myeloma treatment, immunomodulatory agents, monoclonal antibodies, proteasome inhibitors, ADCs, CAR T, TCEs, RRMM biomarkers, treatment sequencing, course in English, course in Spanish, course in French, course in Italian

свернуть